Skip to Content

New Drug Approvals Archive - February 2012

February 2012

Sklice (ivermectin) Lotion

Date of Approval: February 7, 2012
Company: Sanofi Pasteur Inc.
Treatment for: Lice

Sklice (ivermectin) Lotion is a pediculicide indicated for the topical treatment of head lice infestations in patients 6 months of age and older.

Mitosol (mitomycin) Ophthalmic Solution

Date of Approval: February 7, 2012
Company: Mobius Therapeutics, LLC
Treatment for: Glaucoma Surgery

Mitosol (mitomycin) is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery.

Zioptan (tafluprost) Ophthalmic Solution

Date of Approval: February 10, 2012
Company: Merck & Co., Inc.
Treatment for: Glaucoma (Open Angle), Intraocular Hypertension

Zioptan (tafluprost ophthalmic solution) is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Testosterone Gel (testosterone) Topical Gel - formerly Bio-T-Gel

Date of Approval: February 14, 2012
Company: ANI Pharmaceuticals, Inc.
Treatment for: Hypogonadism -- Male

Testosterone gel is a once-daily transdermal testosterone gel for the treatment of male hypogonadism or low testosterone levels.

Korlym (mifepristone) Tablets

Date of Approval: February 17, 2012
Company: Corcept Therapeutics
Treatment for: Cushing's Syndrome

Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance.

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.